1
|
Albala B, Appelmans E, Burress R, De Santi S, Devins T, Klein G, Logovinsky V, Novak GP, Ribeiro K, Schmidt ME, Schwarz AJ, Scott D, Shcherbinin S, Siemers E, Travaglia A, Weber CJ, White L, Wolf‐Rodda J, Vasanthakumar A. The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partners Scientific Board (PPSB). Alzheimers Dement 2024; 20:695-708. [PMID: 37774088 PMCID: PMC10843521 DOI: 10.1002/alz.13483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2023] [Revised: 08/24/2023] [Accepted: 08/27/2023] [Indexed: 10/01/2023]
Abstract
The Alzheimer's Disease Neuroimaging Initiative (ADNI) Private Partners Scientific Board (PPSB) encompasses members from industry, biotechnology, diagnostic, and non-profit organizations that have until recently been managed by the Foundation for the National Institutes of Health (FNIH) and provided financial and scientific support to ADNI programs. In this article, we review some of the major activities undertaken by the PPSB, focusing on those supporting the most recently completed National Institute on Aging grant, ADNI3, and the impact it has had on streamlining biomarker discovery and validation in Alzheimer's disease. We also provide a perspective on the gaps that may be filled with future PPSB activities as part of ADNI4 and beyond. HIGHLIGHTS: The Private Partners Scientific board (PPSB) continues to play a key role in enabling several Alzheimer's Disease Neuroimaging Initiative (ADNI) activities. PPSB working groups have led landscape assessments to provide valuable feedback on new technologies, platforms, and methods that may be taken up by ADNI in current or future iterations.
Collapse
Affiliation(s)
- Bruce Albala
- Eisai Inc.NutleyNew JerseyUSA
- Present address:
Program in Public HealthIrvine and Department of NeurologyUCI School of MedicineUniversity of California856 Health Sciences QuadIrvineCalifornia92697‐3957USA
| | - Eline Appelmans
- Foundation for the National Institutes of HealthNorth BethesdaMarylandUSA
| | - Ramona Burress
- Janssen Research & Development, LLCTitusvilleNew JerseyUSA
- Present address:
Takeda95, Hayden AvenueLexingtonMassachusetts02421USA
| | - Susan De Santi
- Eisai Inc.NutleyNew JerseyUSA
- Life Molecular ImagingBerlinGermany
- Present address:
Eisai Inc.NutleyNew JerseyUSA
| | - Theresa Devins
- Eisai Inc.NutleyNew JerseyUSA
- Present address:
Cognition Therapeutics2500 Westchester AvenuePurchaseNew York10577USA
| | | | - Veronika Logovinsky
- Eisai Inc.NutleyNew JerseyUSA
- Present address:
Lundbeck6 Parkway NDeerfieldIllinois60015USA
| | | | | | | | | | | | | | | | - Alessio Travaglia
- Foundation for the National Institutes of HealthNorth BethesdaMarylandUSA
| | | | - Leah White
- Foundation for the National Institutes of HealthNorth BethesdaMarylandUSA
- Present address:
Veranex5420 Wade Park Blvd Suite 204RaleighNorth Carolina27607USA
| | - Julie Wolf‐Rodda
- Foundation for the National Institutes of HealthNorth BethesdaMarylandUSA
| | | |
Collapse
|
2
|
Somersan-Karakaya S, Turner KC, Cortes-Burgos L, Miller J, LaCroix-Fralish M, Logovinsky V, Patel Y, Torres R, Ganguly S, Breazna A, DeVeaux M, Bhore R, Gao M, Delfino FJ, Rafique A, Fairhurst JL, Hunt C, Babb R, Badithe A, Poueymirou WT, Surowitz R, Rottey S, Murphy AJ, Harari O, Macdonald LE, Croll SD. Monoclonal antibodies against GFRα3 are efficacious against evoked hyperalgesic and allodynic responses in mouse join pain models but, one of these, REGN5069, was not effective against pain in a randomized, placebo-controlled clinical trial in patients with osteoarthritis pain. Neurobiol Pain 2023; 14:100136. [PMID: 38099276 PMCID: PMC10719528 DOI: 10.1016/j.ynpai.2023.100136] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/14/2023] [Revised: 06/22/2023] [Accepted: 06/22/2023] [Indexed: 12/17/2023]
Abstract
The artemin-GFRα3 signaling pathway has been implicated in various painful conditions including migraine, cold allodynia, hyperalgesia, inflammatory bone pain, and mouse knees contain GFRα3-immunoreactive nerve endings. We developed high affinity mouse (REGN1967) and human (REGN5069) GFRα3-blocking monoclonal antibodies and, following in vivo evaluations in mouse models of chronic joint pain (osteoarthritic-like and inflammatory), conducted a first-in-human phase 1 pharmacokinetics (PK) and safety trial of REGN5069 (NCT03645746) in healthy volunteers, and a phase 2 randomized placebo-controlled efficacy and safety trial of REGN5069 (NCT03956550) in patients with knee osteoarthritis (OA) pain. In three commonly used mouse models of chronic joint pain (destabilization of the medial meniscus, intra-articular monoiodoacetate, or Complete Freund's Adjuvant), REGN1967 and REGN5069 attenuated evoked behaviors including tactile allodynia and thermal hyperalgesia without discernably impacting joint pathology or inflammation, prompting us to further evaluate REGN5069 in humans. In the phase 1 study in healthy subjects, the safety profiles of single doses of REGN5069 up to 3000 mg (intravenous) or 600 mg (subcutaneous) were comparable to placebo; PK were consistent with a monoclonal antibody exhibiting target-mediated disposition. In the phase 2 study in patients with OA knee pain, two doses of REGN5069 (100 mg or 1000 mg intravenous every 4 weeks) for 8 weeks failed to achieve the 12-week primary and secondary efficacy endpoints relative to placebo. In addition to possible differences in GFRα3 biology between mice and humans, we highlight here differences in experimental parameters that could have contributed to a different profile of efficacy in mouse models versus human OA pain. Additional research is required to more fully evaluate any potential role of GFRα3 in human pain.
Collapse
Affiliation(s)
| | | | | | - Jutta Miller
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
| | | | | | - Yamini Patel
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
| | - Richard Torres
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
| | - Samit Ganguly
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
| | - Aurora Breazna
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
| | | | - Rafia Bhore
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
| | - Min Gao
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
| | | | - Ashique Rafique
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
| | | | - Charleen Hunt
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
| | - Robert Babb
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
| | - Ashok Badithe
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
| | | | | | | | | | - Olivier Harari
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
| | | | - Susan D. Croll
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
| |
Collapse
|
3
|
Swanson CJ, Logovinsky V, Söderberg L, Johannesson M, Lannfelt L, Möller C, Satlin A. [P2–055]: PHARMACOLOGICAL CHARACTERIZATION OF BAN2401‐MEDIATED Aβ PROTOFIBRIL CLEARANCE BY MICROGLIA. Alzheimers Dement 2017. [DOI: 10.1016/j.jalz.2017.06.704] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
4
|
Swanson CJ, Marson DC, McPherson T, Gerstenecker A, Logovinsky V. [P1–070]: THE FINANCIAL CAPACITY INSTRUMENT–SHORT FORM IS A NOVEL, PERFORMANCE‐BASED MEASURE THAT MAY HELP DIFFERENTIATE MILD COGNITIVE IMPAIRMENT AND MILD DEMENTIA DUE TO ALZHEIMER's DISEASE POPULATIONS IN CLINICAL TRIALS. Alzheimers Dement 2017. [DOI: 10.1016/j.jalz.2017.06.137] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
5
|
Wang J, Logovinsky V, Hendrix SB, Stanworth SH, Perdomo C, Xu L, Dhadda S, Do I, Rabe M, Luthman J, Cummings J, Satlin A. ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials. J Neurol Neurosurg Psychiatry 2016; 87:993-9. [PMID: 27010616 PMCID: PMC5013117 DOI: 10.1136/jnnp-2015-312383] [Citation(s) in RCA: 87] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/01/2015] [Accepted: 02/29/2016] [Indexed: 11/28/2022]
Abstract
BACKGROUND Development of new therapies for Alzheimer's disease (AD) is increasingly focused on more mildly affected populations, and requires new assessment and outcome strategies. Patients in early stages of AD have mild cognitive decline and no, or limited, functional impairment. To respond to these assessment challenges, we developed a measurement approach based on established scale items that exhibited change in previous amnestic Mild Cognitive Impairment (aMCI) trials. METHODS Partial least squares regression with a longitudinal clinical decline model identified items from commonly used clinical scales with the highest combined sensitivity to change over time in aMCI and weighted these items according to their relative contribution to detecting clinical progression in patients' early stages of AD. The resultant AD Composite Score (ADCOMS) was assessed for its ability to detect treatment effect in aMCI/prodromal AD (pAD) clinical trial populations. RESULTS ADCOMS consists of 4 Alzheimer's Disease Assessment Scale-cognitive subscale items, 2 Mini-Mental State Examination items, and all 6 Clinical Dementia Rating-Sum of Boxes items. ADCOMS demonstrated improved sensitivity to clinical decline over individual scales in pAD, aMCI and in mild AD dementia. ADCOMS also detected treatment effects associated with the use of cholinesterase inhibitors in these populations. Improved sensitivity predicts smaller sample size requirements when ADCOMS is used in early AD trials. CONCLUSIONS ADCOMS is proposed as new standard outcome for pAD and mild AD dementia trials, and is progressing in a CAMD-sponsored qualification process for use in registration trials of pAD.
Collapse
Affiliation(s)
- Jinping Wang
- Department of Neuroscience and General Medicine, Eisai Inc., Woodcliff Lake, New York, USA
| | - Veronika Logovinsky
- Department of Neuroscience and General Medicine, Eisai Inc., Woodcliff Lake, New York, USA
| | | | | | - Carlos Perdomo
- Department of Neuroscience and General Medicine, Eisai Inc., Woodcliff Lake, New York, USA
| | - Lu Xu
- Department of Neuroscience and General Medicine, Eisai Inc., Woodcliff Lake, New York, USA
| | - Shobha Dhadda
- Department of Neuroscience and General Medicine, Eisai Inc., Woodcliff Lake, New York, USA
| | - Ira Do
- Department of Neuroscience and General Medicine, Eisai Inc., Woodcliff Lake, New York, USA
| | - Martin Rabe
- Department of Neuroscience and General Medicine, Eisai Inc., Woodcliff Lake, New York, USA
| | - Johan Luthman
- Department of Neuroscience and General Medicine, Eisai Inc., Woodcliff Lake, New York, USA
| | - Jeffrey Cummings
- Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, USA
| | - Andrew Satlin
- Department of Neuroscience and General Medicine, Eisai Inc., Woodcliff Lake, New York, USA
| |
Collapse
|
6
|
Logovinsky V, Satlin A, Lai R, Swanson C, Kaplow J, Osswald G, Basun H, Lannfelt L. Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody. Alzheimers Res Ther 2016; 8:14. [PMID: 27048170 PMCID: PMC4822297 DOI: 10.1186/s13195-016-0181-2] [Citation(s) in RCA: 155] [Impact Index Per Article: 19.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/27/2015] [Accepted: 02/25/2016] [Indexed: 12/14/2022]
Abstract
Background Several monoclonal antibodies for the treatment of Alzheimer’s disease (AD) have been in development over the last decade. BAN2401 is a monoclonal antibody that selectively binds soluble amyloid β (Aβ) protofibrils. Methods Here we describe the first clinical study with BAN2401. Safety and tolerability were investigated in mild to moderate AD. A study design was used with staggered parallel single and multiple ascending doses, from 0.1 mg/kg as a single dose to 10 mg/kg biweekly for four months. The presence of amyloid related imaging abnormalities (ARIA, E for edema, H for hemorrhage) was assessed with magnetic resonance imaging (MRI). Cerebrospinal fluid (CSF) and plasma samples were analyzed to investigate pharmacokinetics (PK) and effects on biomarkers. Results The incidence of ARIA-E/H on MRI was comparable to that of placebo. BAN2401 exposure was approximately dose proportional, with a serum terminal elimination half-life of ~7 days. Only a slight increase of plasma Aβ(1-40) was observed but there were no measurable effects of BAN2401 on CSF biomarkers. On the basis of these findings Phase 2b efficacy study has been initiated in early AD. Conclusions BAN2401 was well-tolerated across all doses. The PK profile has guided us for selecting dose and dose regimens in the ongoing phase 2b study. There was no clear guidance for an effective dose based on biomarkers. Trial registration number NCT01230853 ClinicalTrials.gov Registered October 27, 2010. Electronic supplementary material The online version of this article (doi:10.1186/s13195-016-0181-2) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
| | - Andrew Satlin
- Eisai, Inc., 100 Tice Blvd, Woodcliff Lake, NJ, 07677, USA
| | - Robert Lai
- Eisai, Inc., 100 Tice Blvd, Woodcliff Lake, NJ, 07677, USA
| | - Chad Swanson
- Eisai, Inc., 100 Tice Blvd, Woodcliff Lake, NJ, 07677, USA
| | - June Kaplow
- Eisai, Inc., 100 Tice Blvd, Woodcliff Lake, NJ, 07677, USA
| | - Gunilla Osswald
- BioArctic Neuroscience AB, Warfvinges väg 35, 112 51, Stockholm, Sweden
| | - Hans Basun
- BioArctic Neuroscience AB, Warfvinges väg 35, 112 51, Stockholm, Sweden.,Department of Public Health/Geriatrics, Uppsala University, Dag Hammarskiölds väg 14 B, 751 85, Uppsala, Sweden
| | - Lars Lannfelt
- BioArctic Neuroscience AB, Warfvinges väg 35, 112 51, Stockholm, Sweden. .,Department of Public Health/Geriatrics, Uppsala University, Dag Hammarskiölds väg 14 B, 751 85, Uppsala, Sweden.
| |
Collapse
|
7
|
Satlin A, Wang J, Logovinsky V, Berry S, Swanson C, Dhadda S, Berry DA. Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease. Alzheimers Dement (N Y) 2016; 2:1-12. [PMID: 29067290 PMCID: PMC5644271 DOI: 10.1016/j.trci.2016.01.001] [Citation(s) in RCA: 50] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Introduction Recent failures in phase 3 clinical trials in Alzheimer's disease (AD) suggest that novel approaches to drug development are urgently needed. Phase 3 risk can be mitigated by ensuring that clinical efficacy is established before initiating confirmatory trials, but traditional phase 2 trials in AD can be lengthy and costly. Methods We designed a Bayesian adaptive phase 2, proof-of-concept trial with a clinical endpoint to evaluate BAN2401, a monoclonal antibody targeting amyloid protofibrils. The study design used dose response and longitudinal modeling. Simulations were used to refine study design features to achieve optimal operating characteristics. Results The study design includes five active treatment arms plus placebo, a clinical outcome, 12-month primary endpoint, and a maximum sample size of 800. The average overall probability of success is ≥80% when at least one dose shows a treatment effect that would be considered clinically meaningful. Using frequent interim analyses, the randomization ratios are adapted based on the clinical endpoint, and the trial can be stopped for success or futility before full enrollment. Discussion Bayesian statistics can enhance the efficiency of analyzing the study data. The adaptive randomization generates more data on doses that appear to be more efficacious, which can improve dose selection for phase 3. The interim analyses permit stopping as soon as a predefined signal is detected, which can accelerate decision making. Both features can reduce the size and duration of the trial. This study design can mitigate some of the risks associated with advancing to phase 3 in the absence of data demonstrating clinical efficacy. Limitations to the approach are discussed.
Collapse
Affiliation(s)
- Andrew Satlin
- Neuroscience & General Medicine, Eisai Inc., Woodcliff Lake, NJ, USA
| | - Jinping Wang
- Neuroscience & General Medicine, Eisai Inc., Woodcliff Lake, NJ, USA
| | | | | | - Chad Swanson
- Neuroscience & General Medicine, Eisai Inc., Woodcliff Lake, NJ, USA
| | - Shobha Dhadda
- Neuroscience & General Medicine, Eisai Inc., Woodcliff Lake, NJ, USA
| | | |
Collapse
|
8
|
Logovinsky V, Wessels AM, Novak G, Do I, Chandler J, Harper‐Mozley L, Rabe M, Raghavan N, Luthman PJ. F4‐03‐01: POPULATION CHARACTERIZATION IN THE EARLY STAGES OF ALZHEIMER'S DISEASE. Alzheimers Dement 2014. [DOI: 10.1016/j.jalz.2014.04.372] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
| | | | - Gerald Novak
- Janssen Research & DevelopmentTitusvilleNew JerseyUnited States
| | - Ira Do
- Eisai Inc.Woodcliff LakeNew JerseyUnited States
| | | | | | - Martin Rabe
- Eisai Inc.Woodcliff LakeNew JerseyUnited States
| | | | | |
Collapse
|
9
|
Logovinsky V, Swanson C, Lai R, Do I, Kaplow JM, Rabe MP, Gordon R, Wang J, Xu L, Basun H, Lannfelt L, Satlin A. P4‐181: INITIAL LEARNINGS FROM SCREENING STRATEGIES IN THE BAN 2401‐G000‐201 TRIAL: AN EARLY ALZHEIMER'S DISEASE STUDY. Alzheimers Dement 2014. [DOI: 10.1016/j.jalz.2014.05.1698] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
| | | | - Robert Lai
- Eisai Ltd.HatfieldHertfordshireUnited Kingdom
| | - Ira Do
- Eisai Inc.Woodcliff LakeNew JerseyUnited Kingdom
| | | | | | | | | | - Lu Xu
- Eisai Inc.Woodcliff LakeNew JerseyUnited States
| | | | | | | |
Collapse
|
10
|
Lannfelt L, Möller C, Basun H, Osswald G, Sehlin D, Satlin A, Logovinsky V, Gellerfors P. Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease. Alzheimers Res Ther 2014; 6:16. [PMID: 25031633 PMCID: PMC4054967 DOI: 10.1186/alzrt246] [Citation(s) in RCA: 100] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
The symptomatic drugs currently on the market for Alzheimer's disease (AD) have no effect on disease progression, and this creates a large unmet medical need. The type of drug that has developed most rapidly in the last decade is immunotherapy: vaccines and, especially, passive vaccination with monoclonal antibodies. Antibodies are attractive drugs as they can be made highly specific for their target and often with few side effects. Data from recent clinical AD trials indicate that a treatment effect by immunotherapy is possible, providing hope for a new generation of drugs. The first anti-amyloid-beta (anti-Aβ) vaccine developed by Elan, AN1792, was halted in phase 2 because of aseptic meningoencephalitis. However, in a follow-up study, patients with antibody response to the vaccine demonstrated reduced cognitive decline, supporting the hypothesis that Aβ immunotherapy may have clinically relevant effects. Bapineuzumab (Elan/Pfizer Inc./Johnson & Johnson), a monoclonal antibody targeting fibrillar Aβ, was stopped because the desired clinical effect was not seen. Solanezumab (Eli Lilly and Company) was developed to target soluble, monomeric Aβ. In two phase 3 studies, Solanezumab did not meet primary endpoints. When data from the two studies were pooled, a positive pattern emerged, revealing a significant slowing of cognitive decline in the subgroup of mild AD. The Arctic mutation has been shown to specifically increase the formation of soluble Aβ protofibrils, an Aβ species shown to be toxic to neurons and likely to be present in all cases of AD. A monoclonal antibody, mAb158, was developed to target Aβ protofibrils with high selectivity. It has at least a 1,000-fold higher selectivity for protofibrils as compared with monomers of Aβ, thus targeting the toxic species of the peptide. A humanized version of mAb158, BAN2401, has now entered a clinical phase 2b trial in a collaboration between BioArctic Neuroscience and Eisai without the safety concerns seen in previous phase 1 and 2a trials. Experiences from the field indicate the importance of initiating treatment early in the course of the disease and of enriching the trial population by improving the diagnostic accuracy. BAN2401 is a promising candidate for Aβ immunotherapy in early AD. Other encouraging efforts in immunotherapy as well as in the small-molecule field offer hope for new innovative therapies for AD in the future.
Collapse
Affiliation(s)
- Lars Lannfelt
- Department of Public Health/Geriatrics, Uppsala University, Dag Hammarskölds väg 14 B, 751 85 Uppsala, Sweden ; BioArctic Neuroscience AB, Warfvinges väg 35, 112 51 Stockholm, Sweden
| | - Christer Möller
- BioArctic Neuroscience AB, Warfvinges väg 35, 112 51 Stockholm, Sweden
| | - Hans Basun
- Department of Public Health/Geriatrics, Uppsala University, Dag Hammarskölds väg 14 B, 751 85 Uppsala, Sweden ; BioArctic Neuroscience AB, Warfvinges väg 35, 112 51 Stockholm, Sweden
| | - Gunilla Osswald
- BioArctic Neuroscience AB, Warfvinges väg 35, 112 51 Stockholm, Sweden
| | - Dag Sehlin
- Department of Public Health/Geriatrics, Uppsala University, Dag Hammarskölds väg 14 B, 751 85 Uppsala, Sweden
| | - Andrew Satlin
- Eisai, Inc, 100 Tice Boulevard, Woodcliff Lake, NJ 07677, USA
| | | | - Pär Gellerfors
- BioArctic Neuroscience AB, Warfvinges väg 35, 112 51 Stockholm, Sweden
| |
Collapse
|
11
|
Satlin A, Lai R, Gee M, Swanson C, Kaplow J, Albala B, Logovinsky V. Use of PET imaging to screen subjects for trials in prodromal and Mild Alzheimer's disease and the relationship between PET and CSF findings. Neurobiol Aging 2014. [DOI: 10.1016/j.neurobiolaging.2014.01.103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
12
|
Yu Y, Logovinsky V, Schuck E, Kaplow J, Chang MK, Miyagawa T, Wong N, Ferry J. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel γ-secretase modulator, E2212, in healthy human subjects. J Clin Pharmacol 2014; 54:528-36. [PMID: 24343761 DOI: 10.1002/jcph.249] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2013] [Accepted: 12/09/2013] [Indexed: 01/19/2023]
Abstract
E2212, a novel γ-secretase modulator, is under development for the treatment of Alzheimer's disease. The safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending oral doses (10-250 mg, double-blind, placebo-controlled, randomized) of E2212 were evaluated. In this phase I clinical trial, E2212 was found to be well tolerated in single doses. Maximum tolerated dose was not achieved up to 250 mg. Most AEs were mild to moderate in severity with no identifiable dose related pattern. There were no clinically significant findings on physical and ophthalmologic examinations as well as vital signs, laboratory, ECG and C-SSRS assessments. E2212 was rapidly absorbed, with median tmax values ranging from 0.5 to 1.0 h. E2212 exhibited biphasic disposition with the terminal t1/2 of 12.5-19.0 h. Renal excretion was the minor pathway for E2212 elimination. Increased PD response (reduction in plasma concentrations of Aβ(x-42)) was observed with increasing doses. The maximum PD response was observed in the highest dose 250 mg cohort, with ΔAUAC(0-24 h) of 44.1% and Amax of 53.6%. These results support further clinical development of E2212.
Collapse
Affiliation(s)
- Yanke Yu
- Drug Metabolism and Pharmacokinetics, Eisai Inc., Andover, MA, USA
| | | | - Edgar Schuck
- Drug Metabolism and Pharmacokinetics, Eisai Inc., Andover, MA, USA
| | - June Kaplow
- Department of Biostatistics, Eisai Inc., Woodcliff Lake, NJ, USA
| | - Min-Kun Chang
- Department of Biostatistics, Eisai Inc., Woodcliff Lake, NJ, USA
| | | | - Nancy Wong
- Drug Metabolism and Pharmacokinetics, Eisai Inc., Andover, MA, USA
| | - Jim Ferry
- Department of Clinical Pharmacology, Eisai Inc., Woodcliff Lake, NJ, USA
| |
Collapse
|
13
|
Stephenson D, Aviles E, Bain LJ, Brumfield M, Carrillo M, Comery TA, Compton C, Corrigan B, Gordon MF, Jack CR, Katz R, Logovinsky V, Satlin A, Marek K, Nicholas T, Polhamus D, Angersbach BS, Raghavan N, Romano G, Romero K, Shaw L, Woodcock J, Vradenburg G, Isaac M. Coalition Against Major Diseases: Precompetitive Collaborations and Regulatory Paths to Accelerating Drug Development for Neurodegenerative Diseases. Ther Innov Regul Sci 2013; 47:632-638. [DOI: 10.1177/2168479013498386] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
14
|
Navia B, Perdomo C, Krause S, Kaplow JM, Koyama A, Teceno T, Gershman B, Logovinsky V, Swanson C, Lai R, Möller C, Lannfelt L, Satlin A, McCracken P. P4–282: A multimodal imaging study of mAb158, a murine monoclonal antibody with high selectivity for amyloid protofibrils, in Tg2576 mice. Alzheimers Dement 2013. [DOI: 10.1016/j.jalz.2013.05.1675] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
| | | | | | | | | | | | | | | | - Chad Swanson
- Eisai Inc. Woodcliff Lake New Jersey United States
| | | | | | | | | | | |
Collapse
|
15
|
Romano S, Potkin S, Barlas S, Sperling R, Kalali A, Siemers E, Logovinsky V. P1–398: Designing the next generation of disease modification trials in people with early Alzheimer's disease: Learnings from recently completed programs in mild‐to‐moderate populations. Alzheimers Dement 2013. [DOI: 10.1016/j.jalz.2013.05.625] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
| | - Steven Potkin
- University of California, Irvine Irvine California United States
| | - Suna Barlas
- Pfizer Inc. Collegeville Pennsylvania United States
| | - Reisa Sperling
- Brigham and Women's Hospital Boston Massachusetts United States
| | - Amir Kalali
- Quintiles San Diego California United States
| | - Eric Siemers
- Eli Lilly and Company Indianapolis Indiana United States
| | | |
Collapse
|
16
|
Lai R, Logovinsky V, Kaplow JM, Gu K, Yu Y, Möller C, Navia B, Swanson C, Lannfelt L, Satlin A. O4–05–01: A first‐in‐human study of BAN2401, a novel monoclonal antibody against beta‐amyloid protofibrils. Alzheimers Dement 2013. [DOI: 10.1016/j.jalz.2013.04.358] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
| | | | | | - Kenan Gu
- Eisai Inc. Woodcliff Lake United States
| | - Yanke Yu
- Eisai Inc. Andover Massachusetts United States
| | | | | | | | | | | |
Collapse
|
17
|
Swanson C, Kaplow JM, Mastroeni D, Rogers J, Waara ER, Navia B, Lai R, Logovinsky V, Möller C, Lannfelt L, Satlin A. P4–286: Pharmacology of BAN2401: A monoclonal antibody selective for beta‐amyloid protofibrils. Alzheimers Dement 2013. [DOI: 10.1016/j.jalz.2013.05.1679] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- Chad Swanson
- Eisai Inc. Woodcliff Lake New Jersey United States
| | | | | | - Joseph Rogers
- Banner Sun Health Research Institute Sun City Arizona United States
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Kaplow JM, Kusnetov G, Mastroeni D, Navia B, Kumar N, Biscaro B, Koyama A, Möller C, Lai R, Swanson C, Logovinsky V, Lannfelt L, Satlin A, Rogers J. P4–281: Microglial involvement and amyloid reduction with BAN2401/mAb158, a monoclonal antibody with high selectivity for protofibrils:
In vitro
and
ex vivo
analyses. Alzheimers Dement 2013. [DOI: 10.1016/j.jalz.2013.05.1674] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Chad Swanson
- Eisai Inc. Woodcliff Lake New Jersey United States
| | | | | | | | - Joseph Rogers
- Banner Sun Health Research Institute Sun City Arizona United States
| |
Collapse
|
19
|
Carrillo MC, Brashear HR, Logovinsky V, Ryan JM, Feldman HH, Siemers ER, Abushakra S, Hartley DM, Petersen RC, Khachaturian AS, Sperling RA. Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease. Alzheimers Dement 2013; 9:123-131.e1. [PMID: 23411394 DOI: 10.1016/j.jalz.2012.12.004] [Citation(s) in RCA: 73] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Current research including the basic biology of Alzheimer's disease (AD) provides a foundation to explore whether our current state of knowledge is sufficient to initiate prevention studies and allow us to believe prevention of AD is possible. Current research and recently revised criteria for the diagnosis of AD by the National Institutes on Aging and the Alzheimer's Association suggest a continuum of disease from preclinical asymptomatic to symptomatic Alzheimer's dementia. In light of these revised criteria, the possibility of secondary prevention and even primary prevention is under discussion. The Alzheimer's Association Research Roundtable convened a meeting to discuss the rationale and feasibility of conducting secondary prevention trials in AD.
Collapse
|
20
|
Hendrix S, Logovinsky V, Perdomo C, Wang J, Satlin A. P4‐305: Introducing a new tool for optimizing responsiveness to decline in early Alzheimer's disease. Alzheimers Dement 2012. [DOI: 10.1016/j.jalz.2013.08.086] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
21
|
Nagy C, Schuck E, Ishibashi A, Nakatani Y, Rege B, Logovinsky V. P3‐415: E2012, a novel gamma‐secretase modulator, decreases plasma amyloid‐beta (Aβ) levels in humans. Alzheimers Dement 2010. [DOI: 10.1016/j.jalz.2010.05.1958] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
22
|
Logovinsky V, Hurt SW, Wang Q, Moline ML, Hsu T. P1‐167: Modeling conversion to dementia of the Alzheimer's type in a study of mild cognitive impairment. Alzheimers Dement 2008. [DOI: 10.1016/j.jalz.2008.05.755] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
| | | | - Qin Wang
- Eisai Global Clinical DevelopmentRidgefield ParkNJUSA
| | | | - Timothy Hsu
- Eisai Global Clinical DevelopmentRidgefield ParkNJUSA
| |
Collapse
|
23
|
|
24
|
Logovinsky V, Kaposi AD, Vanderkooi JM. Native and denatured Zn cytochrome c studied by fluorescence line narrowing spectroscopy. Biochim Biophys Acta 1993; 1161:149-60. [PMID: 8381668 DOI: 10.1016/0167-4838(93)90208-9] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Fluorescence Line Narrowing (FLN) spectroscopy was employed to compare the environment around the porphyrin in folded and unfolded Zn-substituted cytochrome c (Zn cyt c). Parameters of the resolved spectra, including the inhomogeneous energy-distribution function, vibrational energy levels, and phonon coupling, were compared for guanidine-denatured Zn cyt c and native Zn cyt c. The spectra of denatured Zn cyt c showed increased broad background and decreased peak resolution when compared to the native protein, indicating that denaturation results in increased phonon coupling. The energy-distribution function for the unfolded protein was fitted to a single Gaussian centered at 17,230 cm-1 with a width of approx. 360 cm-1, which proved to be blue shifted and much wider than that for native Zn cyt c (approx. 65 cm-1). Vibrational frequencies of the ground-state for Zn cyt c were identified and shown to change upon denaturation. Temperature-dependence of the FLN spectra of native Zn cyt c was analyzed and found to have step-like broadening between 40 K and 50 K. Such discontinuous spectral broadening behavior suggests that a discrete conformational change occurs in the protein at these temperatures.
Collapse
Affiliation(s)
- V Logovinsky
- Department of Biochemistry and Biophysics, School of Medicine, University of Pennsylvania, Philadelphia 19104
| | | | | |
Collapse
|
25
|
|
26
|
Bauer JD, Logovinsky V, Skinner JL. Renormalization‐group approach to the metal–insulator transition in doped semiconductors. J Chem Phys 1989. [DOI: 10.1063/1.455968] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
|